SOURCE-LINKED STUDY SUMMARY
Long-term Safety and Efficacy of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: Results From a 52-Week Open-Label Extension Trial.
Abstract summarizedQuality not appraised
- What was studied
- An open-label extension followed weekly growth-hormone replacement.
- Who / model studied
- 220 adults with GH deficiency who completed the parent trial.
- Studied dose & schedule
- Weekly lonapegsomatropin for a 52-week extension after the 38-week parent trial. All received active treatment; exact doses were not in the abstract.
- What the study found
- Body-composition improvements were maintained or improved relative to parent-trial baseline through up to 90 weeks. Injection-site reactions occurred in 5.1%, mild or moderate. Respiratory infections and headache were common events.
- Limitations & context
- Selected completers and no concurrent placebo group. Replacement in GH deficiency cannot establish healthy-person hypertrophy. Abstract assessment; detailed glucose and serious-event data unavailable.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/j.eprac.2026.08.028